Although PKCα is a therapeutic target for glioblastoma, a previous study showed no clinical benefits in patients with high-grade gliomas following treatment with the antisense oligonucleotide aprinocarsen directed against PKCα [78]. This evidence concerns the gene PRKCA and glioma.